<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="develop">
            <roleset id="develop.01" name="" wordnet="10">
                <roles>
                    <role n="0" descr="non-intentional theme&#x0A;" />
                    <role n="1" descr="thing developed&#x0A;" />
                    <role n="2" descr="end result&#x0A;" />
                </roles>
              
                <example src="EGRAM" no="*0">
                    <text>Although Pin1 -/- mice have previously been found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                    <arg n="0">mice</arg>
                    <arg n="M-MAN">normally</arg>
                </example>
              <example src="EGRAM" no="*0">
                <text>Although Pin1 -/- mice have previously been found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*0">
                <text>Although Pin1 -/- mice have been found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*0">
                <text>Although Pin1 -/- mice have been found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
                <example src="EGRAM" no="*1">
                    <text>Although Pin1 -/- mice have previously been predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                    <arg n="0">mice</arg>
                    <arg n="M-MAN">normally</arg>
                </example>
              <example src="EGRAM" no="*1">
                <text>Although Pin1 -/- mice have previously been predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1">
                <text>Although Pin1 -/- mice have been predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1">
                <text>Although Pin1 -/- mice have been predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1b">
                <text>Although Pin1 -/- mice have previously been shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1b">
                <text>Although Pin1 -/- mice have been shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1b">
                <text>Although Pin1 -/- mice have been shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
              <example src="EGRAM" no="*1c">
                <text>Although Pin1 -/- mice have previously been believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1c">
                <text>Although Pin1 -/- mice have previously been believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1c">
                <text>Although Pin1 -/- mice have been believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1c">
                <text>Although Pin1 -/- mice have been believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were previously predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were previously believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were previously shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are previously found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were previously found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice are found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*1d">
                <text>Although Pin1 -/- mice were found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
             
                <example src="EGRAM" no="*2">
                    <text>Although Pin1 -/- mice have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                    <arg n="0">mice</arg>
                    <arg n="M-MAN">normally</arg>
                </example>
              <example src="EGRAM" no="*2">
                <text>Although Pin1 -/- mice have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
                <example src="EGRAM" no="*3">
                    <text>Although Pin1 -/- mice can previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                    <arg n="0">mice</arg>
                    <arg n="M-MAN">normally</arg>
                </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice can have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice could previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice can develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice can have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice could develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>

              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice may previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice may have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice might previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice may develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice may have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice might develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>

              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice will previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice will have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice would previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice will develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice will have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice would develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>

              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice are previously able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice were previously able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice are able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              <example src="EGRAM" no="*3">
                <text>Although Pin1 -/- mice were able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.</text>
                <arg n="0">mice</arg>
                <arg n="M-MAN">normally</arg>
              </example>
              
                <example src="EGRAM" no="4">
                    <text>It is planted from September up to the end of October, and develops into the rosette stage and keeps on growing until the end of November.</text>
                    <arg n="0">It</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>It has been planted from September up to the end of October, and has developed into the rosette stage and keeps on growing until the end of November.</text>
                    <arg n="0">It</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>It will be planted from September up to the end of October, and will develop into the rosette stage and keeps on growing until the end of November.</text>
                    <arg n="0">It</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
              <example src="EGRAM" no="6">
                <text>It will be planted from September up to the end of October, and will obviously develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
                <example src="EGRAM" no="7">
                    <text>It is planted from September up to the end of October, and can develop into the rosette stage and keeps on growing until the end of November.</text>
                    <arg n="0">It</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and can obviously develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and may develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and may obviously develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and is able to develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and is predicted to develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and will be shown to develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It has been planted from September up to the end of October, and has been observed to develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and has the ability to develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="7">
                <text>It is planted from September up to the end of October, and is believed to develop into the rosette stage and keeps on growing until the end of November.</text>
                <arg n="0">It</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
                <example src="EGRAM" no="8">
                    <text>Spinach sown in October developed into the rosette stage and grew through the end of November.</text>
                    <arg n="1">Spinach sown in October</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Spinach sown in October has developed into the rosette stage and grown through the end of November.</text>
                    <arg n="1">Spinach sown in October</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
              <example src="EGRAM" no="9">
                <text>Spinach sown in October is developing into the rosette stage and will grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="9">
                <text>Spinach sown in October has been developing into the rosette stage and can grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
                <example src="EGRAM" no="10">
                    <text>Spinach sown in October that develops into the rosette stage grows through the end of November.</text>
                    <arg n="1">Spinach sown in October</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
              <example src="EGRAM" no="10">
                <text>Spinach sown in October that can develop into the rosette stage grows through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="10">
                <text>Spinach sown in October that is able to develop into the rosette stage grows through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
                <example src="EGRAM" no="11">
                    <text>Spinach sown in October which develops into the rosette stage grows through the end of November.</text>
                    <arg n="1">Spinach sown in October</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
              <example src="EGRAM" no="11">
                <text>Spinach sown in October which can develop into the rosette stage grows through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="11">
                <text>Spinach sown in October which is able to develop into the rosette stage grows through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="11">
                <text>Spinach sown in October being able to develop into the rosette stage grows through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="11">
                <text>Spinach sown in October developing into the rosette stage grows through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
                <example src="EGRAM" no="12">
                    <text>Spinach sown in October will develop into the rosette stage and grow through the end of November.</text>
                    <arg n="1">Spinach sown in October</arg>
                    <arg n="2">the rosette stage</arg>
                </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October will have developed into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October would develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October can develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October can have developed into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October could develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October may develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October may have developed into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October might develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October is able to develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October was able to develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October is believed to develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October was believed to develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October is shown to develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October was shown to develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October is predicted to develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October was predicted to develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>

              <example src="EGRAM" no="12">
                <text>Spinach sown in October is found to develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October was found to develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>>
              
              <example src="EGRAM" no="12">
                <text>Spinach sown in October has the ability to develop into the rosette stage and grow through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              <example src="EGRAM" no="12">
                <text>Spinach sown in October had the ability to develop into the rosette stage and grew through the end of November.</text>
                <arg n="1">Spinach sown in October</arg>
                <arg n="2">the rosette stage</arg>
              </example>
              
                <example src="EGRAM" no="*13">
                    <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son develops acute neonatal onset of OTC deficiency.</text>
                    <arg n="0">whose son</arg>
                    <arg n="1">acute neonatal onset of OTC deficiency</arg>
                </example>
                <example src="EGRAM" no="*14">
                    <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son has developed acute neonatal onset of OTC deficiency.</text>
                    <arg n="0">whose son</arg>
                    <arg n="1">acute neonatal onset of OTC deficiency</arg>
                </example>
                <example src="EGRAM" no="*15">
                    <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son will develop acute neonatal onset of OTC deficiency.</text>
                    <arg n="0">whose son</arg>
                    <arg n="1">acute neonatal onset of OTC deficiency</arg>
                </example>
              <example src="EGRAM" no="*15">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son will have developed acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*15">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son would develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
                <example src="EGRAM" no="*16">
                    <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son can develop acute neonatal onset of OTC deficiency.</text>
                    <arg n="0">whose son</arg>
                    <arg n="1">acute neonatal onset of OTC deficiency</arg>
                </example>
              <example src="EGRAM" no="*16">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son can have developed acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*16">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son could develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*16">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is developing acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*16">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was developing acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*16">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son has been developing acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
                <example src="EGRAM" no="*17">
                    <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son may develop acute neonatal onset of OTC deficiency.</text>
                    <arg n="0">whose son</arg>
                    <arg n="1">acute neonatal onset of OTC deficiency</arg>
                </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son may have developed acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son might develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is able to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son has the ability to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son had the ability to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son has the risk of developing acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son had the risk of developing acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is observed to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was observed to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is predicted to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was predicted to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is found to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was found to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is shown to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was shown to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is believed to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              <example src="EGRAM" no="*17">
                <text>A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was believed to develop acute neonatal onset of OTC deficiency.</text>
                <arg n="0">whose son</arg>
                <arg n="1">acute neonatal onset of OTC deficiency</arg>
              </example>
              
              
              
                <example src="EGRAM" no="*18">
                    <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we develop a novel screening system.</text>
                  <arg n="0">we</arg>
                  <arg n="1">a novel screening system</arg>
                </example>
                <example src="EGRAM" no="*19">
                    <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we developed a novel screening system.</text>
                  <arg n="0">we</arg>
                  <arg n="1">a novel screening system</arg>
                </example>
                <example src="EGRAM" no="*20">
                    <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have developed a novel screening system.</text>
                  <arg n="0">we</arg>
                  <arg n="1">a novel screening system</arg>
                </example>
                <example src="EGRAM" no="*21">
                    <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we will develop a novel screening system.</text>
                  <arg n="0">we</arg>
                  <arg n="1">a novel screening system</arg>
                </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we will have developed a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we would develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we can develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we can have developed a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we could develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we may develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we may have developed a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we might develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we decide to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we decided to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have decided to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we choose to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we chose to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have chosen to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we are able to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
              <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we were able to develop a novel screening system.</text>
              <arg n="0">we</arg>
              <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have been able to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we are ready to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we were ready to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have been ready to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have the ability to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
              <example src="EGRAM" no="*21">
                <text>To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we had the ability to develop a novel screening system.</text>
                <arg n="0">we</arg>
                <arg n="1">a novel screening system</arg>
              </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
